| International Session（Symposium）4(JSGS・JSGE・JGES) |
| Fri. November 6th 14:30 - 17:00 Room 2: Kobe International Exhibition Hall No.2 Building Hall (South) |
| Current status of Robotic surgery for rectal cancer | |||
| Yusuke Kinugasa1, Takatoshi Matsuyama1, Masanori Tokunaga1 | |||
| 1Department of Gastrointestinal Surgery, Tokyo Medical and Dental University | |||
|
|||
|
|||
| There are more than 400 da Vinci systems in Japan. Robotic rectal cancer surgery was approved for national health insurance since April 2018 in Japan. The number of Robotic rectal cancer surgery has increased more than 3 times in Japan. We performed 650 robotic rectal cancer surgery from 2011 to 2017 in Shizuoka cancer center hospital, and 200 in TMDU from 2017 to 2019. Robotic surgery was superior to laparoscopic surgery in a hospital stay, blood loss conversion rate and frequency of urinary retention in our cases. Moreover, in robotic surgery, we can mobilize the rectum into the anal canal easily. Therefore, even in very low rectal cancer which was indication for ISR could be performed LAR. In Japan, lateral lymph node dissection is the standard treatment for locally advanced lower rectal cancer. The indication of the lateral lymph node dissection is lower rectal cancer with T3 or T4. Lower rectal cancer was defined as rectal cancer below the peritoneal reflection. Lateral lymph node dissection is a good indication of robotic surgery. We performed more than 200 robotic surgeries with lateral lymph node dissection for lower advanced rectal cancer and got better outcome compared by open approach. |
|||
|
Index Term 1: Robotic Surgery Index Term 2: Rectal cancer surgery |
|||
| Page Top | |||